| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_897e99b3535b9ad4db01b0afbd240671
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_530ca929bacea312ac11f499da61a1ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1777 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b74121bd159f3ca43312d449d9c83fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fa61392583599c4397b9b76e0bfcba8 |
| publicationDate |
2012-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012175711-A1 |
| titleOfInvention |
Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy |
| abstract |
The present invention relates to an ex vivo method for predicting the responsiveness of a patient affected with an osteosarcoma to chemotherapy, comprising the step of determining the level expression of at least one marker selected in the group consisting of β5 integrin, FAK or GSK-3β in a tumor sample from said patient. Moreover, the invention relate to an antagonist of β5 integrin, FAK or GSK-3β or an inhibitor of the expression of β5 integrin, FAK or GSK-3β for use in a method for enhancing clinical efficiency of chemotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2930248-A1 |
| priorityDate |
2011-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |